791 related articles for article (PubMed ID: 33405101)
1. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
[TBL] [Abstract][Full Text] [Related]
2. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
3. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
6. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
He C; Li W; Xie Q; Yin G
Front Immunol; 2021; 12():820163. PubMed ID: 35116041
[TBL] [Abstract][Full Text] [Related]
9. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
Yeung TW; Cheong KN; Lau YL; Tse KN
Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
[TBL] [Abstract][Full Text] [Related]
10. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease.
Harada H; Shoda H; Tsuchiya H; Misaki M; Sawada T; Fujio K
Rheumatol Int; 2024 May; 44(5):961-971. PubMed ID: 38456909
[TBL] [Abstract][Full Text] [Related]
12. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.
Shirakashi M; Nakashima R; Tsuji H; Tanizawa K; Handa T; Hosono Y; Akizuki S; Murakami K; Hashimoto M; Yoshifuji H; Ohmura K; Mimori T
Rheumatology (Oxford); 2020 Nov; 59(11):3284-3292. PubMed ID: 32276271
[TBL] [Abstract][Full Text] [Related]
15. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
18. Fatal and extensive multiorgan hemorrhages in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: An autopsy case report.
Watanabe T; Takizawa N; Nagasaka T; Nakamura Y; Ikai H; Yamamoto M; Murai Y; Takasugi K; Yokoyama-Kokuryo W; Fujita Y
Medicine (Baltimore); 2020 Jan; 99(3):e18600. PubMed ID: 32011440
[TBL] [Abstract][Full Text] [Related]
19. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
20. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
